Zostavax is a live, attenuated varicella-zoster virus (weakened chickenpox virus).
Zostavax is indicated for adults 50 years of age or older that helps to boost the immune system against herpes zoster virus, Shingles.
Zostavax is given as a single dose by injection under the skin.
Zostavax cannot be used to treat Shingles or the nerve pain that may follow Shingles, once you have it.
Clinical Trial NCT03120364: Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
- This is a phase 3 multi-center, randomized, double-blinded, parallel-group study to assess the Immunogenicity and safety of NBP608 compared to Zostavax which are indicated for the prevention of herpes zoster.
- Total of 824 healthy subjects aged 50 and over, each subject is administered with a single dose of vaccine which is randomly assigned in 1:1 ratio. Stratified randomization for age group is used to achieve the balance of treatment assignment within age strata.
- Total of five visits scheduled including two visits via telephone contact. Blood sampling is conducted for immunogenicity assessment before and 6 weeks after vaccination at Visit 2 and Visit 4 respectively. Safety is monitored 1 week, 6 weeks and 26 weeks after vaccination through Visit 3*, Visit 4 and Visit 5* (* telephone contact)